A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, Biphasic Insulin Aspart 30, 50 and 70.
Status:
Completed
Trial end date:
2006-08-01
Target enrollment:
Participant gender:
Summary
The hypothesis is that an optimal formulation of fast acting and intermediary acting insulin
analogues will improve post prandial glycaemic control in patients with type 1 diabetes.
OBJECTIVE:
The objective is to describe pharmacodynamic (PD) and pharmacokinetic (PK) profiles of
Insulin Aspart (IAsp), Biphasic Insulin Aspart (BIAsp) 30, 50 and 70 for a period of 12 hours
following a standard test meal on four days respectively in subjects with type 1 diabetes.